Apolipoprotein C-III bound to apolipoprotein B-containing lipoproteins in obese girls

Clinical Chemistry

Volumn 49, Issue 2, 2003, Pages 303-306

  Blackett, Piers R ^a,d   Germany, Robin ^b   Sambo, Boureima ^b   Alaupovic, Petar ^c  

^a Department of Pediatrics ^*  (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c OK Medical Research Foundation   (United States)

^d Children's Hospital Oklahoma City   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN C3; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; OBESITY; PROTEIN BLOOD LEVEL; RISK FACTOR; SYNDROME X; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; APOLIPOPROTEIN C-III; APOLIPOPROTEINS B; APOLIPOPROTEINS C; FEMALE; HUMANS; LIPOPROTEINS; OBESITY; PROTEIN BINDING;

EID: 0037307058     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/49.2.303     Document Type: Article

References (48)

1. Colditz GA, Willett WC, Stampfer MJ, Manson JE, Hennekens CH, Arky RA, et al. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol 1990;132:501-13.
2. Sorlie P, Gordon T, Kannel WB. Body build and mortality. The Framingham Study. JAMA 1980;243:1828-31.
3. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Monson RR, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990;322:882-9.
4. Bergstrom E, Hernell O, Persson LA, Vessby B. Insulin resistance syndrome in adolescents. Metabolism 1996;45:908-14.
5. Arslanian S, Suprasongsin C. Insulin sensitivity, lipids, and body composition in childhood: is "syndrome X" present? J Clin Endocrinol Metab 1996;81:1058-62.
6. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation 1990;81:470-6.
7. Campos H, Perlov D, Khoo C, Sacks FM. Distinct patterns of lipoproteins with apoB defibed by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia. J Lipid Res 2001;42:1239-49.
8. Austin MA, Breslow JL, Hennekens CH; Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988;260:1917-21.
9. Orchard TJ, Becker DJ, Bates M, Kuller LH, Drash AL. Plasma insulin and lipoprotein concentrations: an atherogenic association? Am J Epidemiol 1983;118:326-37.
10. Terry RB, Wood PD, Haskell WL, Stefanick ML, Krauss RM. Regional adiposity patterns in relation to lipids, lipoprotein cholesterol, and lipoprorein subfraction mass in men. J Clin Endocrinol Metab 1989;68:191-9.
11. Kikuchi DA, Srinivasan SR, Harsha DW, Webber LS, Sellers TA, Berenson GS. Relation of serum lipoprotein lipids and apolipoproteins to obesity in children: the Bogalusa Heart Study. Prev Med 1992;21:177-90.
12. Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 1985;75:384-90.
13. Aalto-Setala K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, et al. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest 1992;90:1889-900.
14. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, et al. Triglyceride-and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994;90:42-9.
15. Hammer LD, Kraemer HC, Wilson DM, Ritter PL, Dornbusch SM. Standardized percentile curves of body-mass index for children and adolescents. Am J Dis Child 1991;145:259-63.
16. Flegal KM, Ogden CL, Wei R, Kuczmarski RL, Johnson CL. Prevalence of overweight in US Children: comparison of US growth charts from the Centers for Disease Control and Prevention with other reference values for body mass index. Am J Clin Nutr 2001;73:1086-93.
17. Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R, et al. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics 2002;109:45-60.
18. Deurenberg P, Weststrate JA, Hautvast JG. Changes in fat-free mass during weight loss measured by bioelectrical impedance and by densitometry. Am J Clin Nutr 1989;49:33-6.
19. Bjorntorp P. Abdominal obesity and risk. Clin Exp Hypertens A 1990;12:783-94.
20. Lipid Research Clinics Program. The manual of laboratory operations for lipid and lipoprotein analysis [Abstract]. DHEW Publication No. NIH 75-6288. Bethesda, MD: NIH, 1974.
21. Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 1970;11:583-95.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
23. Curry MD, McConathy WJ, Fesmire JD, Alaupovic P. Quantitative determination of human apotipoprotein C-III by electroimmunoassay. Biochim Biophys Acta 1980;617:503-13.
24. Morgan CR, Lazarow A. Immunoassay of pancreatic and plasma insulin following alloxan injection of rats. Diabetes 1965;14:669-71.
25. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani E, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63.
26. Berenson GS, Wattigney WA, Tracy RE, Newman WP 3rd, Srinivasan SR, et al. Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study). Am J Cardiol 1992;70:851-8.
27. Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: Effect of 5-hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 2001;88:265-9.
28. Leroux G, Lemieux I, Lamarche B, Cantin B, Dagenais GR, Lupien PJ, et al. Influence of triglyceride concentration on the relationship between lipoprotein cholesterol and apolipoprotein B and A-1 levels. Metabolism 2000;49:53-61.
29. Chan DC, Watts GF, Barrett PH, Mamo JC, Redgrave TG. Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. Clin Chem 2002;48:278-83.
30. Chajek T, Eisenberg S. Very low density lipoprotein. Metabolism of phospholipids, cholesterol, and applipoprotein C in the isolated perfused rat heart. J Clin Invest 1978;61:1654-65.
31. Murdoch SJ, Breckenridge WC. Effect of lipid transfer proteins on lipoprotein lipase induced transformation of VLDL and HDL. Biochim Biophys Acta 1996;1303:222-32.
32. Alaupovic P, Blackenhorn DH, Knight-Gibson C, Tavella M, Bard JM, et al. apoB-containing lipoprotein particles as risk factors for coronary artery disease. Adv Exp Med Biol 1991;285:299-309.
33. Sadur CN, Eckel RH. Insulin stimulation of adipose tissue lipoprotein lipase. Use of the euglycemic clamp technique. J Clin Invest 1982;69:1119-25.
34. Eisenberg S, Patsch JR, Sparrow JT, Gotto AM, Olivecrona T. Very low density lipoprotein. Removal of apolipoproteins C-II and C-III-1 during lipolysis in vitro. J Biol Chem 1979;254:12603-8.
35. Eisenberg S, Olivecrona T. Very low density lipoprotein. Fate of phospholipids, cholesterol, and apolipoprotein C during lipolysis in vitro. J Lipid Res 1979;20:614-23.
36. Chen M, Breslow JL, Li W, Leff T. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J Lipid Res 1994;35:1918-24.
37. Dallinga-Thie GM, Groenendijk M, Blom RN, De Bruin TW, De Kant E. Genetic heterogeneity in the apolipoprotein C-III promoter and effects of insulin. J Lipid Res 2001;42:1450-6.
38. Windler E, Chao Y, Havel RJ. Regulation of the hepatic uptake of triglyceriderich lipoproteins in the rat. Opposing effects of homologous apolipoprotein E and individual C apoproteins. J Biol Chem 1980;255:8303-7.
39. Luc G, Fievet C, Arveller D, Evans AE, Bard JM, Cambien F, et al. Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Temoins sur 'Infarctus du Myocarde. J Lipid Res 1996;37:508-17.
40. Gervaise N, Garrigue MA, Lasfargues G, Lecomte P. Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in type II diabetes. Diabetologia 2000;43:703-8.
41. Lee S-J, Moye LA, Sacks FM. ApoB lipoproteins containing ApoC3 are risk factors for recurrent coronary events in diabetic patients. Diabetes 2001; 50(Suppl 2):A7,290R.
42. Hirsch GA, Vaid N, Blumenthal RS. Perspectives: the significance of measuring non-HDL-cholesterol. Prev Cardiol 2002;5:156-9.
43. Thompson GR. Angiographic evidence for the role of triglyceride-rich lipoproteins in progression of coronary artery disease. Eur Heart J 1998;19(Suppl H):H31-6.
44. Frost PH, Havel RJ. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol 1998;81:26B-31B.
45. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
46. Caprio S, Bronson M, Sherwin RS, Rife F, Tamborlane WV. Co-existence of severe insulin resistance and hyperinsulinaemia in pre-adolescent obese children. Diabetologia 1996;39:1489-97.
47. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. Diabetes, blood lipids, and the role of obesity in coronary heart disease risk for women. The Framingham Study. Ann Intern Med 1977;87:393-7.
48. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992;41:715-22.